Adverse Events of BRAF and MEK Inhibitors
Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different.
Each type of cancer treatment has its own adverse event (AE) profile, and BRAF and MEK inhibitors are no different, explained Michael A. Postow, MD, medical oncologist at Memorial Sloan Kettering Cancer Center.
In advanced melanoma, AEs may differ depending on the drug combination that a patient is prescribed. Those who are on dabrafenib (Tafinlar) and trametinib (Mekinist) are more likely to experience fever and chills. And if they do, it is important that providers hold treatment until these symptoms go away.
Patients prescribed vemurafenib (Zelboraf) plus cobimetinib (Cotellic) may be more likely to experience skin-related AEs, and need to be careful when it comes to sun exposure.
Finally, patients who take encorafenib (Braftovi) and binimetinib (Mektovi) may be more susceptible to arthralgia.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
